首页 > 市场调查报告书 > 製药

疫苗

市场调查报告书

商品编码

1461274

流感疫苗市场，按疫苗类型，按效价，按给药途径，按年龄组，按技术，按配销通路，按地理

Influenza Vaccines Market, By Vaccine Type, By Valency, By Route of Administration, By Age Group, By Technology, By Distribution Channel, By Geography

出版日期: 2024年03月18日 | 出版商:

Coherent Market Insights | 英文 197 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2024年流感疫苗市值为83亿美元，预计2031年将达到134.3亿美元，2024年至2031年的年复合成长率（CAGR）为7.1%。

报告范围		报告详情
基准年：	2023年	2023/2024 年市场规模：	83亿美元
历史数据：	2019年至2023年	预测期：	2024年至2031年
预测期间 2023/2024 至 2030/2031 年复合成长率：	7.10%	2030/2031 价值预测：	134.3 亿美元

2024 年按地区分類的流感疫苗市占率 (%)

预计 2024 年全球流感疫苗市场价值为 83 亿美元，预计在预测期内（2024-2031 年）复合年增长率为 7.1%。几十年来，流感疫苗一直是预防保健的重要组成部分。流感病毒具有定期变异和进化的能力，因此需要每年开发更新的疫苗。这些疫苗可以增强人体对这些不断变化的病毒的免疫反应。它们旨在针对三种或四种病毒株（取决于特定流感季节使用的疫苗类型）进行免疫，监测和其他科学研究已确定这些病毒株最有可能在任何特定地区即将到来的流感季节流行。由于人们对季节性疫苗接种的认识不断增强、新技术的引入、医疗保健组织扩大疫苗接种指南以及全球政府的支持不断增加，全球流感疫苗市场在过去几年中稳步增长。

市场动态：

全球流感疫苗市场的成长是由多种因素推动的，例如流感盛行率的增加、国际卫生组织制定的疫苗接种指南的日益采用、疫苗接种意识的提高、新产品的推出、对重组技术疫苗的日益偏好以及地理范围的扩大。然而，由于开发四价流感疫苗涉及高昂的研发成本、批准新疫苗的严格监管指南以及由于流感病毒株抗原漂移而产生的疫苗抗药性，市场成长可能面临挑战。由于医疗基础设施的改善和可支配收入的增加，市场参与者看到了新兴国家的机会。製造商也致力于开发针对多种流感病毒株具有持久保护作用的通用流感疫苗。

研究的主要特点：

该报告对全球流感疫苗市场进行了深入分析，并提供了以2023年为基准年的预测期（2024-2031年）的市场规模（十亿美元）和年复合成长率（CAGR%）。
它阐明了不同细分市场的潜在收入机会，并解释了该市场有吸引力的投资主张矩阵。
这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
它根据以下参数介绍了全球流感疫苗市场的主要参与者——公司亮点、产品组合、主要亮点、财务表现和策略。
该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
全球流感疫苗市场报告迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
利害关係人可以透过用于分析全球流感疫苗市场的各种策略矩阵轻鬆做出决策。

介绍
北美洲
我们
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
拉丁美洲其他地区
欧洲
德国
英国
法国
义大利
西班牙
俄罗斯
欧洲其他地区
亚太地区
中国
印度
日本
澳洲
韩国
东协
亚太地区其他地区
中东
海湾合作委员会
以色列
中东其他地区
非洲
南非
中非
北非

第 12 章：竞争格局

热图分析
市占率分析
- CSL Seqirus
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- FluGen, Inc.
- Moderna, Inc.
- Biocryst Pharmaceuticals Inc.
- CPL Biologicals Pvt. Ltd.
- CureVac AG
- OSIVAX
- Solaris Vaccines
- Pfizer
- Daiichi Sankyo
- Bharat Biotech
- Sinovac Biotech
- Solaris Vaccines

第 13 章：分析师观点

命运之轮
分析师观点
连贯的机会图

第 14 章：参考文献与研究方法

参考
研究方法论

简介目录

Product Code: CMI1705

The influenza vaccines market is estimated to be valued at USD 8.30 Bn in 2024 and is expected to reach USD 13.43 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.1% from 2024 to 2031.

Report Coverage		Report Details
Base Year:	2023	Market Size in 2023/2024:	US$ 8.30 Bn
Historical Data for:	2019 to 2023	Forecast Period:	2024 to 2031
Forecast Period 2023/2024 to 2030/2031 CAGR:	7.10%	2030/2031 Value Projection:	US$ 13.43 Bn

Influenza Vaccines Market Share (%), By Region, 2024

Global influenza vaccines market is estimated to be valued at USD 8.30 BN in 2024 and is expected to exhibit a CAGR of 7.1% during the forecast period (2024-2031). Influenza vaccines have been an important element of preventive healthcare for decades. The influenza viruses have the ability to mutate and evolve regularly, necessitating the development of updated vaccines each year. The vaccines work to boost the body's immune response to these changing viruses. They are designed to immunize against the three or four strains (depending on the vaccine type used for a particular flu season) that surveillance and other scientific studies have determined are most likely to be in circulation for the upcoming flu season in any given region. The global influenza vaccines market has witnessed steady growth over the past few years due to the growing awareness about seasonal vaccination, introduction of novel technologies, expansion of vaccination guidelines by healthcare organizations, and rising government support worldwide.

Market Dynamics:

The global influenza vaccines market growth is driven by various factors such as the increasing prevalence of influenza, growing adoption of vaccination guidelines set by international health organizations, rising awareness about vaccination, new product launches, growing preference for recombinant technology vaccines, and expansion in geographical reach of major players. However, the market growth can be challenging due to high R&D costs involved for development of quadrivalent influenza vaccines, stringent regulatory guidelines for approval of new vaccines and vaccine resistance arising due to antigenic drift of influenza virus strains. The market players see opportunities in emerging countries owing to improving healthcare infrastructure and rising disposable incomes. Manufacturers are also working on the development of universal influenza vaccine with durable protection against multiple flu strains.

Key Features of the Study:

This report provides an in-depth analysis of the global influenza vaccines market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the global influenza vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
Key companies covered as a part of this study includes Seqirus, GlaxoSmithKline plc, Sanofi, AstraZeneca, FluGen Inc., Moderna Inc., Biocryst Pharmaceuticals Inc., CPL Biologicals Pvt. Ltd., CureVac AG, OSIVAX, Solaris Vaccines, Pfizer, CSL, Daiichi Sankyo, Bharat Biotech, and Sinovac Biotech.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
The global influenza vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global influenza vaccines market.

Market Segmentation

Vaccine Type:
- Inactivated
- Live Attenuated
Valency:
- Quadrivalent
- Trivalent
Route of Administration:
- Injection
- Nasal Spray
Age Group:
- Pediatrics
- Adults
Technology:
- Egg-Based Flu Vaccines
- Cell Culture-Based Flu Vaccines
- Recombinant Flu Vaccines
Distribution Channel:
- Public
- Private
Regional:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Seqirus
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- FluGen Inc.
- Moderna Inc.
- Biocryst Pharmaceuticals Inc.
- CPL Biologicals Pvt. Ltd.
- CureVac AG
- OSIVAX
- Solaris Vaccines
- Pfizer
- CSL
- Daiichi Sankyo
- Bharat Biotech
- Sinovac Biotech

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Vaccine Type
- Market Snapshot, By Valency
- Market Snapshot, By Route of Administration
- Market Snapshot, By Age Group
- Market Snapshot, By Technology
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Opportunity
Impact Analysis
Key Developments
Industry Trends
Regulatory Scenario
Recent Product Approval/Launches
PEST Analysis
Porter's Analysis

4. Global Influenza Vaccines Market- Impact of Coronavirus (COVID-19) Pandemic

Impact on Demand
Impact on Healthcare
Epidemiology

5. Global Influenza Vaccines Market, By Vaccine Type, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Inactivated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)
Live Attenuated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

6. Global Influenza Vaccines Market, By Valency, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Quadrivalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)
Trivalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

7. Global Influenza Vaccines Market, By Route of Administration, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)
Nasal Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD BN)

8. Global Influenza Vaccines Market, By Age Group, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)
Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)

9. Global Influenza Vaccines Market, By Technology, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Egg-Based Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)
Cell Culture-Based Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)
Recombinant Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)

10. Global Influenza Vaccines Market, By Distribution Channel, 2019 - 2031, (USD BN)

Introduction
- Market Share Analysis, 2024 and 2031 (%)
- Y-o-Y Growth Analysis, 2019 - 2031
- Segment Trends
Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)
Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2019 - 2031, (USD BN)

11. Global Influenza Vaccines Market, By Region, 2019 - 2031 (USD BN)

Introduction
- Market Share Analysis, By Region, 2024 and 2031(%)
- Y-o-Y Growth Analysis, For Regions, 2019 - 2031
- Regional Trends
North America
- Market Size and Forecast, By Vaccine Type, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Valency, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Route of Administration, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Age Group, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Technology, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Country, 2019 - 2031 (USD BN)
U.S.
Canada
Latin America
- Market Size and Forecast, By Vaccine Type, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Valency, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Route of Administration, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Age Group, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Technology, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Country, 2019 - 2031 (USD BN)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Vaccine Type, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Valency, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Route of Administration, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Age Group, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Technology, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Country, 2019 - 2031 (USD BN)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Vaccine Type, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Valency, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Route of Administration, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Age Group, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Technology, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Country, 2019 - 2031 (USD BN)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Vaccine Type, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Valency, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Route of Administration, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Age Group, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Technology, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Country, 2019 - 2031 (USD BN)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Vaccine Type, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Valency, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Route of Administration, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Age Group, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Technology, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2019 - 2031 (USD BN)
- Market Size and Forecast, By Region/Country, 2019 - 2031 (USD BN)
South Africa
Central Africa
North Africa

12. Competitive Landscape

Heat Map Analysis
Market Share Analysis
- CSL Seqirus
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- FluGen, Inc.
- Moderna, Inc.
- Biocryst Pharmaceuticals Inc.
- CPL Biologicals Pvt. Ltd.
- CureVac AG
- OSIVAX
- Solaris Vaccines
- Pfizer
- Daiichi Sankyo
- Bharat Biotech
- Sinovac Biotech
- Solaris Vaccines